Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Cannabis Withdrawal

In brief

This study is a randomized, double-blind, placebo and active-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to severe cannabis use disorder (CUD). Study participants will receive PP-01, nabilone, or placebo every day for 34 days. The total study duration will be approximately 78 days, including screening and a one-week inpatient stay. Following the initial inpatient portion of the study, participants will return to the clinic for six clinic visits and complete two telemedicine appointments. Participants will complete daily symptom diaries and other study-related questionnaires. Participants who complete the core study may be eligible to participate in a repeat dosing extension study if they meet required criteria.

Key facts

Study ID

NCT07644052

Run by

PleoPharma, Inc.

People needed

420

Starts

2026-06-17

Expected to finish

2027-09-01

Last updated by the study team

2026-08-05

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Generally healthy adults between the ages of 18 and 55, inclusive.
• Meet DSM-5 diagnostic criteria for current moderate to severe CUD as confirmed by a licensed physician or psychologist or addiction medicine specialist. An individual with documented experience in the diagnosis of CUD may be qualified upon Sponsor approval.
• BMI within 18.0 to 38.0 kg/m2, inclusive.
• Female participants must not be pregnant or lactating. Nonpregnancy will be confirmed for all females by a urine pregnancy test conducted at Screening and at the Randomization Visit prior to enrollment into the study.
• If of childbearing potential - the participant agrees to use one of the accepted contraceptive regimens from Screening to the first administration of the study medication, during the study, and for at least 30 days after the last dose of the study medication. An acceptable method of contraception includes one of the following:
• Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
• Intrauterine device (with or without hormones)
• OR agrees to use a double barrier method (e.g., condom and spermicide) during the study and for at least 30 days after the last dose of the study medication
• The Investigator can use their judgement and familiarity with the participant's preferred and usual lifestyle to understand which form of birth control would be the best and also to determine if abstinence is an option what would achieve 100% effectiveness
• Females of non-childbearing potential - should be surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or be postmenopausal (at least 1 year without menses)
• Male participants who are fertile and engage in sexual activity must agree to use a double barrier method (e.g., condom and spermicide) and agree to not donate sperm during the study and for at least 90 days after the last dose of the study medication.
• Be seeking and motivated to discontinue cannabis and to minimize withdrawal symptoms related to cannabis discontinuation.
• Agree to not use cannabis or any product containing CBD, hemp derivatives, terpenes or any THC containing product including delta-8, delta-10, THC-A or any other cannabinoid-like product following Randomization and throughout the study duration.
• Have experienced cravings for cannabis and at least three withdrawal symptoms as defined by DSM-5 Cannabis Withdrawal Syndrome diagnostic criteria within the past year when previously trying to discontinue or reduce use of cannabis
• Meet Criterion C on the DSM-5 Cannabis Withdrawal Diagnostic Criteria
• Participants should be self-reported heavy cannabis users ("medical marijuana" users are allowed) who report use of cannabis multiple times per day at least 6 days per week for at least 6 months:
• Self-reported use of an approximate average of at least 1.5 grams or greater each day of dry leaf flower, or the equivalent (as defined by the participant) of other forms of cannabis
• Must use cannabis during the Screening period for an average of 6 out of 7 days per week and must use the day prior to Randomization
• Have a urine drug screen positive for THC-COOH and have a negative result for all other illicit/excluded drugs at Screening and Randomization and a negative urine for alcohol at Randomization.
• Capable of giving informed consent and stated willingness to comply with all study procedures including inpatient and weekly outpatient visits, daily evening video calls, restrictions, and availability for the duration of the study.
• Willing to be admitted to an inpatient clinic with overnight stays on Days 1 through 6 and return for all outpatient visits.
• Ability to take study drug capsules, agree to daily monitoring of study drug intake during the outpatient period, and have a regular schedule such that daily monitoring and study drug capsule intake can be done at approximately the same time each day.
• Have regular access to the internet and access to video/virtual capabilities for video calls by any means.
• Agree to not use any alcohol during the study.
• Nicotine users must agree to continue their current nicotine use.

You may not qualify if…

• Participants with history or significant presence of any of the following criteria should be excluded from enrollment into the study:
• Lifetime history of DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.
• Current DSM-5 criteria for a psychiatric disorder that in the Investigator's judgment is unstable, would be disrupted by the study medication, or is likely to require new pharmacotherapy or psychotherapy during the study period. Individuals who are currently stable on psychotropic medication for at least 3 months may be included at the discretion of the Investigator's judgement.
• Participants who meet DSM-5 criteria for any history of or current drug use disorder within the previous 2 years, other than cannabis, nicotine, or caffeine use disorders.
• Participants who consume alcohol on a regular or frequent basis and who do not agree or are deemed by the Investigator to be unable to discontinue alcohol for the duration of the study.
• Participants using cannabis for a physician directed medical condition requiring use such as epilepsy.
• Unstable medical conditions, such as AIDS, cancer, uncontrolled hypertension, Type 1 diabetes or uncontrolled or multi-dose insulin treated Type 2 diabetes, pulmonary hypertension, or heart disease.
• Positive test results for HIV-1/HIV-2 Ag/Ab, HBsAg, or HCVAb unless previously treated and successfully cleared of Hepatitis C virus.
• Current or recent history of significant violent or suicidal behavior, risk for suicide or homicide:
• Participants with any suicidal behavior or answering "yes" to Question 4 or 5 on suicidal ideation within the past 1 year based on the Screening version of the C-SSRS
• History of clinically significant hepatic, renal, cardiovascular, pulmonary, hematologic, neurological, psychiatric, gastrointestinal, endocrine, oncologic, immunologic, dermatologic disease of any etiology (including infections), or any other condition that, in the opinion of the Principal Investigator, would jeopardize the safety of the participant or impact the validity of the study results.
• Presence or history of clinically significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability, with the exception that cholecystectomy is permitted at the discretion of the Investigator.
• Any clinically important abnormalities on Screening PE, assessments, ECG, or laboratory tests, including but not limited to:
• Hemoglobin < 10.0 g/dL
• Serum creatinine:
• Central lab: Serum creatinine > 1.30 mg/dL for females or > 1.52 mg/dL for males
• Non-central lab: Serum creatinine > 30% above the ULN for the laboratory used
• Serum bilirubin > 1.5 times ULN, unless documented Gilbert's Disease; AST or ALT > 1.5 times ULN
• Clinically significant abnormal fasting glucose For criteria a, b, c, and d the test can be repeated one time during the Screening period at the discretion of the Investigator. If this option is used the last obtained reading will be used for determination of eligibility. Averages will not be used.
• Hypertension at Screening or Randomization; participants with elevated sitting BP, defined as greater than 145 mmHg systolic or greater than 95 mmHg diastolic
• Use of more than 3 antihypertensive medications for the treatment of hypertension (where an antihypertensive combination of 2 or more products would be considered as separate products) may be permitted at the discretion of the Medical Monitor
• Hypotension at Screening or Randomization; participants with sitting BP lower than 85 mmHg systolic or lower than 55 mmHg diastolic
• Clinically significant abnormal HR or RR based on Investigator judgment For criteria e, f and/or g two repeat measurements within 10 minutes of the first BP are permitted at the discretion of the Investigator. If this option is used the last obtained reading will be used for determination of eligibility. Averages will not be used.
• A clinically significant abnormal 12-lead ECG, such as myocardial infarction, other findings suggestive of ischemia, or prolonged QT/QTc interval, defined as:
• Corrected QT interval using Fridericia's formula > 450 msec for males and > 470 msec for females at Randomization, mean values are allowed to be assessed

Where it is running

• Woodland International Research Group, LLC — Little Rock, Arkansas, United States (enrolling)
• Woodland Research Northwest, LLC — Rogers, Arkansas, United States (enrolling)
• Yale Stress Center — New Haven, Connecticut, United States (enrolling)
• University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - DeLand Clinical Research Unit — DeLand, Florida, United States (enrolling)
• Research Centers of America — Hollywood, Florida, United States (enrolling)
• Sandhill Research, LLC d/b/a Accel Research Sites - St. Pete - Largo Clinical Research Unit — Largo, Florida, United States (enrolling)
• ForCare Clinical Research — Tampa, Florida, United States (enrolling)
• Neuroscience Research Institute — West Palm Beach, Florida, United States (enrolling)
• Sandhill Research, LLC d/b/a Accel Research Sites - NeuroStudies Clinical Research Unit 755 — Decatur, Georgia, United States (enrolling)
• Evergreen Clinical Trials — Norcross, Georgia, United States (enrolling)
• CenExel iResearch, LLC — Savannah, Georgia, United States (enrolling)
• AMR Clinical — Lexington, Kentucky, United States (enrolling)
• Maryland Psychiatric Research Center, University of Maryland School of Medicine — Baltimore, Maryland, United States (enrolling)
• Oasis Clinical Research — Las Vegas, Nevada, United States (enrolling)
• Hassman Research Institute, LLC d/b/a CenExel Marlton, NJ — Marlton, New Jersey, United States (enrolling)
• The Research Foundation for Mental Hygiene/ New York State Psychiatric Institute — New York, New York, United States (enrolling)
• Richmond Behavioral Associates — Staten Island, New York, United States (enrolling)
• Neuro-Behavioral Clinical Research, Inc. — North Canton, Ohio, United States (enrolling)
• Coastal Carolina Research Center, LLC — North Charleston, South Carolina, United States (enrolling)
• AMR Clinical — Knoxville, Tennessee, United States (enrolling)
• Community Clinical Research, Inc. — Austin, Texas, United States (enrolling)
• Memorial Hermann Village — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.